Given these findings, assessing TP53 mutation status and HLA LOH could serve as valuable prognostic markers for guiding personalized treatment strategies and improving therapeutic outcomes in patients with HNSCC. The gene discussed is TP53; the disease is head and neck squamous cell carcinoma.